Eton Pharmaceuticals (ETON) Stock Forecast & Price Target
Score
Eton Pharmaceuticals, Inc. price target
| ETON | |
|---|---|
| Low | $68.00 |
| Average | $72.00 |
| High | $78.00 |
| Upside vs current price | +12.6% |
The average target of $72.00 is +12.6% versus the current ETON price of $63.93.
Eton Pharmaceuticals, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 0 |
| Buy | 4 |
| Hold | 0 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
4 analysts cover ETON.
Eton Pharmaceuticals, Inc. EPS and revenue estimates
The estimate table for the Eton Pharmaceuticals, Inc. keeps 2026 EPS $1.09, 2027 EPS $2.08, and years with fewer than three analysts are not filled in.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $1.09 | $149.71M |
| 2027 | $2.08 | $220.38M |
Is Eton Pharmaceuticals, Inc. a buy or sell?
Of the 4 analysts covering Eton Pharmaceuticals, Inc., 4 rate it a buy (0 strong buy and 4 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The ETON consensus label is Buy, beside 4 buy-side ratings and 0 sell-side ratings.
The average target of $72.00 implies +12.6% versus the current price of $63.93.
the Eton Pharmaceuticals, Inc. closes with 4 buy-side ratings and 0 on the sell side. The headcount is Buy.
Reading the Eton Pharmaceuticals, Inc. forecast
There is little daylight between ETON targets. Low $68.00, average $72.00, high $78.00.
From today's $63.93 print, the ETON average target is +12.6% away.
Most of the ETON coverage agrees: 4 of 4 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.
ETON targets have been marked up: $78.00 across the last month versus $70.25 across the last quarter.
ETON coverage is thin at 4 analysts, and one revision moves the average.
Eton Pharmaceuticals, Inc. forecast questions
What is the ETON price target?
The published range for ETON is $68.00 to $78.00, with an average of $72.00. That average is +12.6% versus the current price of $63.93.
Is Eton Pharmaceuticals, Inc. a buy or sell?
Of the 4 analysts covering Eton Pharmaceuticals, Inc., 4 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, which for ETON is 4 on the buy side, 0 at hold, and 0 on the sell side.
What is the EPS estimate for Eton Pharmaceuticals, Inc.?
Analyst EPS estimates for Eton Pharmaceuticals, Inc.: 2026 $1.09, 2027 $2.08.
What is the revenue estimate for Eton Pharmaceuticals, Inc.?
Analyst revenue estimates for Eton Pharmaceuticals, Inc.: 2026 $149.71M, 2027 $220.38M.
How many analysts cover ETON?
4 analysts cover ETON. Their consensus on ETON is Buy, across those 4.